Compare AbbVie Inc (ABBV) vs GXO Logistics Inc (GXO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs GXO Logistics Inc — how do they compare? AbbVie Inc trades at $252.5 (market cap $449.91B), while GXO Logistics Inc trades at $50.09 (market cap $5.89B). The key difference: AbbVie Inc is far larger — about 76.4× GXO Logistics Inc's market cap, and AbbVie Inc pays a 2.72% dividend while GXO Logistics Inc pays none. Which is the better fit depends on your goals.
| ABBV | GXO | |
|---|---|---|
Market Cap | $449.91B | $5.89B |
Sector | Health | Industrials |
52-Week High | $261.07 | $65.59 |
52-Week Low | $184.85 | $45.52 |
Enterprise Value | $513.38B | $11.05B |
Dividend Yield | 2.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $252.61, down 0.84% on the day, with strong technical momentum showing bullish moving average signals. The company demonstrates solid revenue growth, reaching $61.16B in 2025, though net margins have compressed to 5.79%. Recent quarterly earnings consistently beat expectations, with Q1 2026 EPS of $2.65 exceeding the $2.59 forecast. Positive clinical trial results for ELAHERE in ovarian cancer and institutional buying activity support investor confidence.
AbbVie presents a favorable risk-reward profile with 68% analyst buy ratings and a $266.33 consensus price target offering 5.4% upside. Key opportunities include Skyrizi/Rinvoq growth offsetting Humira declines, while risks involve patent expirations in the 2030s and margin pressure. The stock's elevated P/E of 124.83 reflects growth expectations but warrants monitoring of execution against guidance.
GXO trades at $51.16, down 1.52% today, with a bullish technical signal from moving averages and strong analyst support. Recent earnings beats and a record sales pipeline of $2.7 billion highlight operational momentum. The company secured multiple long-term partnerships in Europe, reinforcing its contract logistics leadership.
Outlook remains positive with a consensus price target of $69.33, implying 35% upside. Risks include Amazon's market entry and retail sector exposure. Revenue growth and margin expansion in 2026 forecasts support a bullish case, though competition and macro pressures warrant monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About GXO Logistics Inc
GXO is the world's largest pure-play contract logistics provider. It offers cutting-edge supply chain solutions, including automated warehousing and fulfillment, for global blue-chip companies.
Read more on GXO →
